0.7497
price up icon5.59%   0.0397
pre-market  Pre-market:  .76   0.0103   +1.37%
loading
Ocugen Inc stock is traded at $0.7497, with a volume of 5.75M. It is up +5.59% in the last 24 hours and down -3.18% over the past month. Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.71
Open:
$0.735
24h Volume:
5.75M
Relative Volume:
1.26
Market Cap:
$218.40M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-2.7767
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
+2.24%
1M Performance:
-3.18%
6M Performance:
-54.84%
1Y Performance:
+46.43%
1-Day Range:
Value
$0.72
$0.7694
1-Week Range:
Value
$0.695
$0.7694
52-Week Range:
Value
$0.495
$2.105

Ocugen Inc Stock (OCGN) Company Profile

Name
Name
Ocugen Inc
Name
Phone
484-328-4701
Name
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Name
Employee
84
Name
Twitter
@Ocugen
Name
Next Earnings Date
2024-11-08
Name
Latest SEC Filings
Name
OCGN's Discussions on Twitter

Compare OCGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OCGN
Ocugen Inc
0.7497 218.40M 0 -63.08M -72.53M -0.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-15-24 Initiated Maxim Group Buy
Mar-01-23 Upgrade Chardan Capital Markets Neutral → Buy
Aug-23-22 Initiated Mizuho Buy
Jun-15-22 Resumed ROTH Capital Buy
Jun-02-22 Initiated Cantor Fitzgerald Overweight
Jul-26-21 Initiated Noble Capital Markets Outperform
Jun-11-21 Downgrade ROTH Capital Buy → Neutral
May-07-21 Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21 Downgrade Chardan Capital Markets Buy → Neutral
Feb-04-21 Upgrade H.C. Wainwright Neutral → Buy
View All

Ocugen Inc Stock (OCGN) Latest News

pulisher
Jan 21, 2025

Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch

Jan 21, 2025
pulisher
Jan 21, 2025

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? - MSN

Jan 21, 2025
pulisher
Jan 18, 2025

Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

Breakthrough in Sight? Ocugen's OCU200 Targets Vision Loss for Millions in New Clinical Trial - MyChesCo

Jan 18, 2025
pulisher
Jan 17, 2025

Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment - MSN

Jan 17, 2025
pulisher
Jan 16, 2025

Breakthrough in Vision: Ocugen's OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa - MyChesCo

Jan 16, 2025
pulisher
Jan 16, 2025

Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch

Jan 16, 2025
pulisher
Jan 16, 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - Ocugen

Jan 16, 2025
pulisher
Jan 16, 2025

Ocugen, Inc. Announces First Patient Dosed in Phase 1 - GlobeNewswire

Jan 16, 2025
pulisher
Jan 16, 2025

Ocugen Launches Phase 1 Trial for Novel Eye Disease Treatment OCU200 in Diabetic Patients - StockTitan

Jan 16, 2025
pulisher
Jan 14, 2025

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

Jan 14, 2025
pulisher
Jan 14, 2025

Long-term potential revealed for novel modifier gene therapy - Marketscreener.com

Jan 14, 2025
pulisher
Jan 13, 2025

Ocugen Inc. stock falls Monday, underperforms market - MarketWatch

Jan 13, 2025
pulisher
Jan 13, 2025

Ocugen's (OCGN) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa - Ocugen

Jan 13, 2025
pulisher
Jan 13, 2025

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple - GlobeNewswire

Jan 13, 2025
pulisher
Jan 13, 2025

Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial - StockTitan

Jan 13, 2025
pulisher
Jan 10, 2025

Ocugen Inc. stock falls Friday, underperforms market - MarketWatch

Jan 10, 2025
pulisher
Jan 09, 2025

Earnings call transcript: Ocugen Q3 2024 highlights clinical progress By Investing.com - Investing.com Canada

Jan 09, 2025
pulisher
Jan 08, 2025

Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch

Jan 08, 2025
pulisher
Jan 08, 2025

Earnings call transcript: Ocugen Q3 2024 highlights clinical progress - Investing.com

Jan 08, 2025
pulisher
Jan 06, 2025

Ocugen to Present at Oppenheimer Movers in Rare Disease Summit - MSN

Jan 06, 2025
pulisher
Jan 02, 2025

Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch

Jan 02, 2025
pulisher
Jan 01, 2025

Ocugen’s Gene Therapy Trial for Dry AMD Advances - MSN

Jan 01, 2025
pulisher
Dec 27, 2024

Ocugen Inc. stock rises Friday, outperforms market - MarketWatch

Dec 27, 2024
pulisher
Dec 25, 2024

State Street Corp Increases Holdings in Ocugen, Inc. (NASDAQ:OCGN) - MarketBeat

Dec 25, 2024
pulisher
Dec 23, 2024

5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance

Dec 23, 2024
pulisher
Dec 20, 2024

Ocugen Inc. stock rises Friday, still underperforms market - MarketWatch

Dec 20, 2024
pulisher
Dec 19, 2024

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen

Dec 19, 2024
pulisher
Dec 19, 2024

Data and Safety Monitoring Board Reviews Interim Safety - GlobeNewswire

Dec 19, 2024
pulisher
Dec 19, 2024

Ocugen's Eye Treatment Shows Promising Safety Data in Phase 1/2 Trial for Macular Degeneration - StockTitan

Dec 19, 2024
pulisher
Dec 12, 2024

Oppenheimer Movers in Rare Disease Summit - Ocugen

Dec 12, 2024
pulisher
Dec 11, 2024

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen

Dec 11, 2024
pulisher
Dec 11, 2024

Ocugen CEO to Showcase Breakthrough Gene Therapy Programs at Oppenheimer Rare Disease Summit - StockTitan

Dec 11, 2024
pulisher
Dec 09, 2024

Ocugen Inc. stock rises Monday, outperforms market - MarketWatch

Dec 09, 2024
pulisher
Dec 03, 2024

Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference - Ocugen

Dec 03, 2024
pulisher
Dec 03, 2024

Ocugen, Inc. to Present at NobleCon20 Emerging Growth Equity Conference - MSN

Dec 03, 2024

Ocugen Inc Stock (OCGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Ocugen Inc Stock (OCGN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Castillo Kirsten
Director
Nov 22 '24
Buy
0.91
25,000
22,848
75,000
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Cap:     |  Volume (24h):